Citadel Advisors’s Avalo Therapeutics AVTX Stock Holding History

Citadel Advisors’s Portfolio AVTX Stock Details AVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$255K	Buy	+13,800	New	+$218K	﹤0.01%	11494
2025 Q4	–	Sell	-10,900	Closed	-$139K	–	12650
2025 Q3	$139K	Buy	+10,900	New	+$93.7K	﹤0.01%	11597
2022 Q1	–	Sell	-4	Closed	-$18K	–	13551
2021 Q4	$18K	Sell	4 -5	-56%	-$30K	﹤0.01%	13595
2021 Q3	$58K	Buy	9 +1	+13%	+$8.11K	﹤0.01%	13283
2021 Q2	$71K	Buy	8 +4	+100%	+$33.5K	﹤0.01%	13151
2021 Q1	$34K	Buy	+4	New	+$37.8K	﹤0.01%	13009

Other funds holding AVTX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Citadel Advisors's AVTX Position: Q2 2026 in Review

Citadel Advisors increased its Avalo Therapeutics (AVTX) stake by 67% in Q2 2026, buying an estimated $2.06M and bringing the position to 323,833 shares worth $5.98M. The position accounts for ﹤0.01% of the portfolio, ranked #4422.

Citadel Advisors first reported a position in AVTX in Q4 2015 and has held it in 17 quarters since. The position peaked at $7.62M in Q4 2025. 125 funds tracked by Wall St. Rank hold AVTX as of Q2 2026.

Citadel Advisors held 323,833 shares of Avalo Therapeutics worth $5.98M as of Q2 2026.
Citadel Advisors bought 130,098 Avalo Therapeutics shares in Q2 2026, an estimated $2.06M.
Avalo Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #4422 holding.
Citadel Advisors first reported a position in Avalo Therapeutics in Q4 2015 and has held it in 17 quarters since.
Citadel Advisors's Avalo Therapeutics position peaked at $7.62M in Q4 2025.
125 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.